Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in detectable complement receptor type 1 levels on erythrocytes from patients with psoriatic polyarthritis

D Rivas1, J L Riestra-Noriega, J C Torre-Alonso

  • 1Immunology Department, Hospital Central de Asturias, Oviedo, Spain.

British Journal of Rheumatology
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histopathologic prognostic score in colorectal adenocarcinomas.

Anticancer research·1998
Same author

Earlier onset of Alzheimer's disease in men with Down syndrome.

Neurology·1998
Same author

Molecular prophets of death in the fly.

American journal of human genetics·1998
Same author

Is the high level of nitric oxide metabolites a marker in early rejection after experimental islet pancreas transplantation?

Transplantation proceedings·1998
Same author

Structure of the human CD94 C-type lectin gene.

Immunogenetics·1998
Same author

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

Blood·1998
Same journal

Sensorineural hearing loss, iritis and ankylosing spondylitis.

British journal of rheumatology·1999
Same journal

Outcome in systemic vasculitis.

British journal of rheumatology·1999
Same journal

Infection with an unenveloped DNA virus (TTV) associated with non-A to G hepatitis in patients with rheumatoid arthritis.

British journal of rheumatology·1999
Same journal

Aortitis in relapsing polychondritis.

British journal of rheumatology·1999
Same journal

Successful treatment with antithymocyte globulin and cyclosporin A of a severe aplastic anaemia associated with an eosinophilic fasciitis.

British journal of rheumatology·1999
Same journal

Haemophagocytic syndrome in a patient with dermatomyositis.

British journal of rheumatology·1999
See all related articles

Complement receptor type 1 (CR1) levels are significantly lower in psoriatic arthritis patients with polyarthritis. This finding suggests CR1 may play a role in disease severity and progression.

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Psoriatic arthritis (PsA) is a chronic inflammatory disease.
  • Complement receptor type 1 (CR1) is involved in immune regulation.
  • Erythrocyte-bound CR1 (E-CR1) function is crucial in modulating complement activation.

Purpose of the Study:

  • To investigate erythrocyte complement receptor type 1 (CR1) levels in psoriatic arthritis (PsA) patients.
  • To determine if CR1 levels correlate with disease subtypes and clinical parameters in PsA.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to quantify CR1 levels on erythrocyte membranes.
  • Patient groups included axial, polyarthritis, and oligoarthritis forms of PsA.
  • Comparison was made against healthy controls.

Related Experiment Videos

Main Results:

  • A significant decrease in CR1 levels was observed in PsA patients with polyarthritis compared to healthy controls.
  • Non-significant reductions in CR1 levels were noted in axial and oligoarthritis PsA groups.
  • An inverse correlation was found between CR1 levels and the articular index, but not with ESR, CRP, or disease duration.

Conclusions:

  • Reduced erythrocyte CR1 levels are associated with the polyarticular form of psoriatic arthritis.
  • CR1 levels may serve as a potential biomarker for disease activity in PsA.
  • Further research is warranted to explore the therapeutic implications of CR1 modulation in PsA.